MSH3

Somatic CRISPR editing of Msh3 mitigates Huntington's disease pathology in mice.

Huntington's disease

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Colorectal cancer and multiple polyposis

Heterozygous germline MSH3 mutations, and probably MLH3 mutations, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk

Hereditary colorectal cancer — MSH3 or MLH3 deficiency